Satoshi Ohno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Satoshi Ohno has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Masaki Inoue
6 shared publications- Satoru Kyo
Department of Obstetrics and Gynecology, Faculty of Medicine, Shimane University, Izumo 693-8501, Japan
5 shared publications Yumiko Ohno
5 shared publications- Haruo Sugiyama
Department of Cancer Immunology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
4 shared publications - Satoshi Dohi
Department of Obstetrics/Gynecology, Showa University Koto Toyosu Hospital, Tokyo, Japan
4 shared publications Gen-Ichiro Soma
3 shared publications
Latest Publications
- 1 June 2012
- Vol. 32 (6) , 2369-75
Effect of green tea extract on reactive oxygen species produced by neutrophils from cancer patients.
Oxidative stress in cancer patients has been demonstrated to be partly mediated by neutrophils. Although it is reported that natural antioxidants, such as green tea extract, reduce oxidative stress, there is limited evidence of their effects in cancer patients. This study aimed to determine the effect of green tea extract on reactive oxygen species produced by neutrophils from cancer patients. Peripheral blood samples were obtained from eighteen patients with advanced cancer. Green tea extract was added to the blood samples with luminol on Mebiol gel, and luminol-dependent chemiluminescence was measured to monitor the production of reactive oxygen species from migrated neutrophils into the gel, at 37°C. Luminol-dependent chemiluminescence was significantly down-regulated in the presence of green tea extract in a concentration-dependent manner. These results indicate the antioxidant effect of green tea extract on reactive oxygen species produced by neutrophils, which may be effective in reducing oxidative stress in cancer patients.
- 1 June 2012
- Vol. 32 (6) , 2369-75
Effect of green tea extract on reactive oxygen species produced by neutrophils from cancer patients.
Oxidative stress in cancer patients has been demonstrated to be partly mediated by neutrophils. Although it is reported that natural antioxidants, such as green tea extract, reduce oxidative stress, there is limited evidence of their effects in cancer patients. This study aimed to determine the effect of green tea extract on reactive oxygen species produced by neutrophils from cancer patients. Peripheral blood samples were obtained from eighteen patients with advanced cancer. Green tea extract was added to the blood samples with luminol on Mebiol gel, and luminol-dependent chemiluminescence was measured to monitor the production of reactive oxygen species from migrated neutrophils into the gel, at 37°C. Luminol-dependent chemiluminescence was significantly down-regulated in the presence of green tea extract in a concentration-dependent manner. These results indicate the antioxidant effect of green tea extract on reactive oxygen species produced by neutrophils, which may be effective in reducing oxidative stress in cancer patients.
- 1 July 2011
- Vol. 31 (7) , 2441-5
WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report.
We report on Wilms tumor (WT1) peptide immunotherapy in a patient with intractable ovarian cancer patient over an extended period. Immunotherapy using WT1 peptide has been undergoing clinical trials for gynecological cancer. We used WT1 peptide vaccination to treat a 53-year-old woman suffering from ovarian cancer with peritoneal dissemination. After 2 months, her pleural and cardiac effusion had disappeared, and the sum of the longest diameter of the target lesion (in the pelvic mass) was reduced. There was a weak positive correlation between CA125 and mononuclear phagocyte/lymphocyte ratio (Spearman's ϱ=0.275, p=0.015). Intradermally administered WT1 peptide vaccination in a case of intractable ovarian cancer stabilized the disease over the course of one year. However, the immunotherapeutic mechanism of WT1 peptide and immunological escape mechanism for carcinoma cells remain to be elucidated.
- 1 July 2011
- Vol. 31 (7) , 2441-5
WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report.
We report on Wilms tumor (WT1) peptide immunotherapy in a patient with intractable ovarian cancer patient over an extended period. Immunotherapy using WT1 peptide has been undergoing clinical trials for gynecological cancer. We used WT1 peptide vaccination to treat a 53-year-old woman suffering from ovarian cancer with peritoneal dissemination. After 2 months, her pleural and cardiac effusion had disappeared, and the sum of the longest diameter of the target lesion (in the pelvic mass) was reduced. There was a weak positive correlation between CA125 and mononuclear phagocyte/lymphocyte ratio (Spearman's ϱ=0.275, p=0.015). Intradermally administered WT1 peptide vaccination in a case of intractable ovarian cancer stabilized the disease over the course of one year. However, the immunotherapeutic mechanism of WT1 peptide and immunological escape mechanism for carcinoma cells remain to be elucidated.
- 1 August 2010
- Vol. 30 (8) , 3187-92
WT1 expression correlates with angiogenesis in endometrial cancer tissue.
No direct comparison has been made of the relationship between the expression of Wilms' tumor gene WT1 within tumor cells and angiogenesis in vivo. A series of 70 endometrial cancer patients who had undergone a curative resection was studied by immunohistochemistry to determine the correlation between WT1 expression, angiogenesis (proliferation of endothelial cell adhesion molecule-1, PECAM-1/CD31) and angiogenic growth factor (vascular endothelial growth factor, VEGF). A strong association was found between WT1 expression score and mean vascular density (p<0.001, n=70, ϱ=0.568). Immunohistochemistry of serial sections revealed that WT1 and VEGF were co-expressed in the same area of endometrial cancer tissue. Tumor-produced WT1, which may regulate the expression of VEGF, is found to be associated with induction of angiogenesis in endometrial cancer.
- 1 August 2010
- Vol. 30 (8) , 3187-92
WT1 expression correlates with angiogenesis in endometrial cancer tissue.
No direct comparison has been made of the relationship between the expression of Wilms' tumor gene WT1 within tumor cells and angiogenesis in vivo. A series of 70 endometrial cancer patients who had undergone a curative resection was studied by immunohistochemistry to determine the correlation between WT1 expression, angiogenesis (proliferation of endothelial cell adhesion molecule-1, PECAM-1/CD31) and angiogenic growth factor (vascular endothelial growth factor, VEGF). A strong association was found between WT1 expression score and mean vascular density (p<0.001, n=70, ϱ=0.568). Immunohistochemistry of serial sections revealed that WT1 and VEGF were co-expressed in the same area of endometrial cancer tissue. Tumor-produced WT1, which may regulate the expression of VEGF, is found to be associated with induction of angiogenesis in endometrial cancer.
- 1 November 2009
- Vol. 29 (11) , 4779-84
Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy.
The object of this study was to investigate the safety and clinical response of immunotherapy targeting the WT1 (Wilms' tumor 1) gene product in patients with gynecological cancer. Twelve patients with WT1/human leukocyte antigen (HLA)-A*2402-positive gynecological cancer were included in a Phase II clinical trial of WT1 vaccine therapy. In all the patients, the tumors were resistant to standard therapy. The patients received intradermal injections of a HLA-A*2402-restricted, modified 9-mer WT1 peptide every week for 12 weeks. Tumor size, which was measured by computed tomography (CT), was determined every 4 weeks. The responses were analyzed according to Response Evaluation Criteria in Solid Tumors (RECIST). The protocol was well tolerated; only local erythema occurred at the WT1 vaccine injection site. The clinical responses were as follows: stable disease (SD) in 3 patients and progressive disease (PD) in 9 patients. No patients had a complete (CR) or partial response (PR). The disease control rate was 25.0%. Although a small, uncontrolled, nonrandomized trial, this study showed that WT1 vaccine therapy for patients with gynecological cancer was safe and produced a clinical response.
- 1 November 2009
- Vol. 29 (11) , 4779-84
Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy.
The object of this study was to investigate the safety and clinical response of immunotherapy targeting the WT1 (Wilms' tumor 1) gene product in patients with gynecological cancer. Twelve patients with WT1/human leukocyte antigen (HLA)-A*2402-positive gynecological cancer were included in a Phase II clinical trial of WT1 vaccine therapy. In all the patients, the tumors were resistant to standard therapy. The patients received intradermal injections of a HLA-A*2402-restricted, modified 9-mer WT1 peptide every week for 12 weeks. Tumor size, which was measured by computed tomography (CT), was determined every 4 weeks. The responses were analyzed according to Response Evaluation Criteria in Solid Tumors (RECIST). The protocol was well tolerated; only local erythema occurred at the WT1 vaccine injection site. The clinical responses were as follows: stable disease (SD) in 3 patients and progressive disease (PD) in 9 patients. No patients had a complete (CR) or partial response (PR). The disease control rate was 25.0%. Although a small, uncontrolled, nonrandomized trial, this study showed that WT1 vaccine therapy for patients with gynecological cancer was safe and produced a clinical response.
- 1 November 2009
- Vol. 29 (11) , 4887-91
Correlation between WT1 expression and cell proliferation in endometrial cancer.
The Wilms' tumor gene WT1 is overexpressed in endometrial cancer. Although recent studies have revealed that WT1 is a new prognostic factor, it remains unclear whether WT1 plays a pathophysiological role including cell proliferation. A series of 70 endometrial cancer patients who had undergone a curative resection was studied by immunohistochemistry to determine the correlation between WT1 expression and cell proliferation (proliferating cell nuclear antigen; PCNA). WT1 expression was observed in 64 cases (91%). WT1 expression was associated with advanced FIGO stage (p=0.0228), myometrial invasion (p=0.0114) and high-grade histological differentiation (p=0.0004), indicating up-regulation of WT1 expression with tumor progression. A positive correlation between PCNA labeling index and score of WT1 expression was observed (p=0.0081, rho=0.319). These results showed that WT1 might regulate cell proliferation in endometrial cancer.
- 1 November 2009
- Vol. 29 (11) , 4887-91
Correlation between WT1 expression and cell proliferation in endometrial cancer.
The Wilms' tumor gene WT1 is overexpressed in endometrial cancer. Although recent studies have revealed that WT1 is a new prognostic factor, it remains unclear whether WT1 plays a pathophysiological role including cell proliferation. A series of 70 endometrial cancer patients who had undergone a curative resection was studied by immunohistochemistry to determine the correlation between WT1 expression and cell proliferation (proliferating cell nuclear antigen; PCNA). WT1 expression was observed in 64 cases (91%). WT1 expression was associated with advanced FIGO stage (p=0.0228), myometrial invasion (p=0.0114) and high-grade histological differentiation (p=0.0004), indicating up-regulation of WT1 expression with tumor progression. A positive correlation between PCNA labeling index and score of WT1 expression was observed (p=0.0081, rho=0.319). These results showed that WT1 might regulate cell proliferation in endometrial cancer.
- 1 May 2009
- Vol. 29 (5) , 1691-5
Immunohistochemical detection of WT1 protein in endometrial cancer.
The Wilms' tumor gene WT1 is overexpressed in various kinds of solid tumors. However, it remains unclear whether WT1 plays a pathophysiological role in endometrial cancer. A series of 70 endometrial cancer patients who had undergone a curative resection was studied to determine the correlation between WT1 expression, clinicopathological characteristics and prognosis. Tissue specimens were evaluated for WT1 expression by immunohistochemistry. The expression of WT1 was strong in 31 patients (44%) and weak in 39 patients (56%). WT1 overexpression was associated with advanced FIGO stage (p=0.0266), myometrial invasion (p=0.0477) and high-grade histological differentiation (p=0.0049). The expression level of WT1 was found to be a significant predictor of disease relapse in univariate analysis (p=0.0233), but not in multivariate analysis (p=0.4757). These results suggested that tumor-produced WT1 provided additional prognostic information in endometrial cancer patients.
- 1 May 2009
- Vol. 29 (5) , 1691-5
Immunohistochemical detection of WT1 protein in endometrial cancer.
The Wilms' tumor gene WT1 is overexpressed in various kinds of solid tumors. However, it remains unclear whether WT1 plays a pathophysiological role in endometrial cancer. A series of 70 endometrial cancer patients who had undergone a curative resection was studied to determine the correlation between WT1 expression, clinicopathological characteristics and prognosis. Tissue specimens were evaluated for WT1 expression by immunohistochemistry. The expression of WT1 was strong in 31 patients (44%) and weak in 39 patients (56%). WT1 overexpression was associated with advanced FIGO stage (p=0.0266), myometrial invasion (p=0.0477) and high-grade histological differentiation (p=0.0049). The expression level of WT1 was found to be a significant predictor of disease relapse in univariate analysis (p=0.0233), but not in multivariate analysis (p=0.4757). These results suggested that tumor-produced WT1 provided additional prognostic information in endometrial cancer patients.
- 1 October 2004
- Vol. 49 (10) , 828-32
Analgesic efficacy of French maritime pine bark extract in dysmenorrhea: an open clinical trial.
To clarify the effect of Pycnogenol (Horphag Research, Switzerland), French maritime pine bark extract, on menstrual pain. We treated 47 patients with menstrual pain, aged 21-45 years, with Pycnogenol at 30 mg (2 capsules) orally twice a dysmenorrl day. The administration of Pycnogenol began on the eighth day of the first menstrual cycle and continued until the seventh day of the third menstrual cycle. Improvement was evaluated by measuring scores of symptoms during the first and second, and first and third menstrual cycle using the Wilcoxon rank sum test. Treatment with Pycnogenol lowered the pain scores for abdominal pain significantly (p < 0.05) as compared to pretreatment values. Pain relief in the second cycle of treatment was better as compared to the first cycle of treatment, as indicated by a higher level of significance (p < 0.01) and lower median pain score. The number of days with abdominal pain showed a trend toward fewer days with pain; however, the difference failed to reach significance. Relief of back pain was not that pronounced during the first cycle treated with Pycnogenol; the pain scores were not significantly different from those in the pretreatment period. However, continuation of treatment during the second cycle produced significant pain relief (p < 0.01). The number of days with back pain decreased. The number of days with pain was significantly lower (p < 0.01) in the second cycle of treatment with Pycnogenol. Pycnogenol has a potential analgesic effect on menstrual pain.
- 1 October 2004
- Vol. 49 (10) , 828-32
Analgesic efficacy of French maritime pine bark extract in dysmenorrhea: an open clinical trial.
To clarify the effect of Pycnogenol (Horphag Research, Switzerland), French maritime pine bark extract, on menstrual pain. We treated 47 patients with menstrual pain, aged 21-45 years, with Pycnogenol at 30 mg (2 capsules) orally twice a dysmenorrl day. The administration of Pycnogenol began on the eighth day of the first menstrual cycle and continued until the seventh day of the third menstrual cycle. Improvement was evaluated by measuring scores of symptoms during the first and second, and first and third menstrual cycle using the Wilcoxon rank sum test. Treatment with Pycnogenol lowered the pain scores for abdominal pain significantly (p < 0.05) as compared to pretreatment values. Pain relief in the second cycle of treatment was better as compared to the first cycle of treatment, as indicated by a higher level of significance (p < 0.01) and lower median pain score. The number of days with abdominal pain showed a trend toward fewer days with pain; however, the difference failed to reach significance. Relief of back pain was not that pronounced during the first cycle treated with Pycnogenol; the pain scores were not significantly different from those in the pretreatment period. However, continuation of treatment during the second cycle produced significant pain relief (p < 0.01). The number of days with back pain decreased. The number of days with pain was significantly lower (p < 0.01) in the second cycle of treatment with Pycnogenol. Pycnogenol has a potential analgesic effect on menstrual pain.